Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2018 | 2 |
| 2021 | 1 |
| 2025 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun.
JHEP Rep. 2021.
PMID: 33898959
Free PMC article.
Novel and emerging therapies for cholestatic liver diseases.
Goldstein J, Levy C.
Goldstein J, et al.
Liver Int. 2018 Sep;38(9):1520-1535. doi: 10.1111/liv.13880. Epub 2018 Jun 14.
Liver Int. 2018.
PMID: 29758112
Review.
Item in Clipboard
Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?
Wagner M, Fickert P.
Wagner M, et al.
Liver Int. 2018 Jun;38(6):991-994. doi: 10.1111/liv.13744.
Liver Int. 2018.
PMID: 29863313
No abstract available.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.